These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4047259)

  • 21. Significance of nucleo-cytoplasmic maturation asynchrony in multiple myeloma.
    Scudla V; Wiedermann B; Kodousek R; Dusek J; Kamarád V; Indrák K
    Neoplasma; 1986; 33(4):483-92. PubMed ID: 3762809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of criteria in staging in multiple myeloma.
    Pennec Y; Mottier D; Youinou P; Asselain B; Miossec P; Le Goff P; Le Prise PY; Le Menn G
    Haematologia (Budap); 1982; 15(2):221-6. PubMed ID: 7160667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma.
    Henon P; Donatini B; Eisenmann JC; Becker M; Beck-Wirth G
    Bone Marrow Transplant; 1995 Jul; 16(1):19-25. PubMed ID: 7581122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic and therapeutic significance of bone marrow biopsy in multiple myeloma. Analysis of 31 stage II A and III A patients].
    Paule B; Quillard J; Medicis P; Bourgeois P; Grossin M; Bisson M; Kahn MF
    Rev Rhum Mal Osteoartic; 1988 Jan; 55(1):27-32. PubMed ID: 3353673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA-image cytometry and clinical staging systems in multiple myeloma.
    Kropff M; Leo E; Steinfurth G; Esselborn H; Adler CP; Böcking A
    Anticancer Res; 1994; 14(5B):2183-8. PubMed ID: 7840520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the prognosis and response to therapy in multiple myeloma].
    Venturino M; Geniram A; Guarino P; Scio P; Marini U
    Recenti Prog Med; 1984 May; 75(5):451-61. PubMed ID: 6484288
    [No Abstract]   [Full Text] [Related]  

  • 28. Differentiated treatment of myeloma. A non-randomised phase two study.
    Osby E; Reizenstein P
    Anticancer Res; 1984; 4(3):163-4. PubMed ID: 6465855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic factors of multiple myeloma].
    Paule B
    Ann Med Interne (Paris); 1997; 148(8):534-41. PubMed ID: 9538400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Classification, staging and prognostic indices for multiple myeloma].
    Hotta T
    Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Retrospective analysis of patients with multiple myeloma; clinical characteristics and prognostic factors].
    Zdziarska B
    Ann Acad Med Stetin; 1990; 36():179-94. PubMed ID: 2099106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
    Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
    Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Reproducibility of a mathematical model for calculating survival in multiple myeloma].
    Pasqualetti P; Casale R; Colantonio D
    Medicina (Firenze); 1989; 9(2):182-4. PubMed ID: 2811644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma].
    Pasqualetti P; Casale R; Collacciani A; Colantonio D
    Medicina (Firenze); 1989; 9(3):280-2. PubMed ID: 2615598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The prognostic significance of cytological study of the bone marrow in multiple myeloma].
    Iakovleva SV
    Ter Arkh; 2000; 72(7):48-51. PubMed ID: 10983321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors and therapeutic results in multiple myeloma.
    Nagai M; Kitahara T; Minato K; Takenaka T; Konda C; Seki S; Shimoyama M
    Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
    Rajkumar SV; Buadi F
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
    Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.